Nuvectis Pharma, Inc.
NASDAQ Capital MarketTotal Valuation
Nuvectis Pharma, Inc. carries a market capitalization of 246.95M, placing it among publicly traded companies globally.
| Market Cap | 246.95M |
| Enterprise Value | N/A |
Share Statistics
Nuvectis Pharma, Inc. currently has 26.53M shares outstanding.
| Shares Outstanding | 26.53M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -1.64 |
| P/TBV Ratio | 12.23 |
| P/FCF Ratio | -9.48 |
| P/OCF Ratio | -9.48 |
Financial Position
Nuvectis Pharma, Inc. maintains a current ratio of 2.27, meaning it holds 2.3x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 2.27 |
| Quick Ratio | 2.25 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -97.79 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Nuvectis Pharma, Inc.'s stock has gained approximately 4.1387% over the past 52 weeks. The 50-day moving average sits at 9.19, while the 200-day moving average is 7.74.
| Beta (5Y) | N/A |
| 52-Week Price Change | 4.1387% |
| 50-Day Moving Average | 9.19 |
| 200-Day Moving Average | 7.74 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -28.27M, while operating income came in at -28.27M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -28.27M |
| Pretax Income | -27.16M |
| Net Income | -27.16M |
| EBITDA | -28.27M |
| EBIT | -28.27M |
| Earnings Per Share (EPS) | -1.21 |
Balance Sheet
Total book value stands at -105.74M, with working capital of 14.22M providing operational flexibility.
| Cash & Cash Equivalents | 25.13M |
| Total Debt | N/A |
| Net Debt | -25.13M |
| Equity (Book Value) | -105.74M |
| Book Value Per Share | -4.70 |
| Working Capital | 14.22M |
Cash Flow
Nuvectis Pharma, Inc. produced -18.35M in operating cash flow over the past twelve months.
| Operating Cash Flow | -18.35M |
| Capital Expenditures | N/A |
| Free Cash Flow | -18.35M |
| FCF Per Share | -0.82 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -7.83 |
| FCF Yield | -10.55 |
Scores
Nuvectis Pharma, Inc. posts an Altman Z-Score of 0.51, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 0.51 |